Free Trial
OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

Genmab A/S logo
$210.11 +1.76 (+0.84%)
As of 12:23 PM Eastern

About Genmab A/S Stock (OTCMKTS:GNMSF)

Key Stats

Today's Range
$210.00
$210.11
50-Day Range
$178.74
$220.51
52-Week Range
$170.00
$292.80
Volume
61 shs
Average Volume
2,905 shs
Market Capitalization
$13.88 billion
P/E Ratio
11.99
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

GNMSF MarketRank™: 

Genmab A/S scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Genmab A/S.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 11.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.74.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 11.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.11% of the outstanding shares of Genmab A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 246.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.11% of the outstanding shares of Genmab A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 246.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genmab A/S has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Genmab A/S has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Genmab A/S this week, compared to 2 articles on an average week.
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Genmab announces share buy-back transactions
See More Headlines

GNMSF Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $207.38 on January 1st, 2025. Since then, GNMSF shares have increased by 0.5% and is now trading at $208.35.
View the best growth stocks for 2025 here
.

Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings results on Thursday, May, 8th. The company reported $3.05 EPS for the quarter, beating analysts' consensus estimates of $1.88 by $1.17. The company earned $765.14 million during the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a trailing twelve-month return on equity of 19.75% and a net margin of 36.30%.

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/08/2025
Today
5/27/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:GNMSF
Employees
1,660
Year Founded
1999

Profitability

Trailing P/E Ratio
11.89
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1.14 billion
Pretax Margin
42.57%

Debt

Sales & Book Value

Annual Sales
$3.12 billion
Cash Flow
$14.18 per share
Price / Cash Flow
14.69
Book Value
$80.53 per share
Price / Book
2.59

Miscellaneous

Free Float
65,057,000
Market Cap
$13.77 billion
Optionable
Not Optionable
Beta
1.02

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (OTCMKTS:GNMSF) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners